Adiabatic Control of Decoherence-Free-Subspaces in an Open Collective System

We propose a method to adiabatically control an atomic ensemble using a decoherence-free subspace (DFS) within a dissipative cavity. We can engineer a specific eigenstate of the system's Lindblad jump operators by injecting a field into the cavity which deconstructively interferes with the emission amplitude of the ensemble. In contrast to previous adiabatic DFS proposals, our scheme creates a DFS in the presence of collective decoherence. We therefore have the ability to engineer states that have high multi-particle entanglements which may be exploited for quantum information science or metrology. We further demonstrate a more optimized driving scheme that utilizes the knowledge of possible diabatic evolution gained from the so-called adiabatic criteria. This allows us to evolve to a desired state with exceptionally high fidelity on a time scale that does not depend on the number of atoms in the ensemble. By engineering the DFS eigenstate adiabatically, our method allows for faster state preparation than previous schemes that rely on damping into a desired state solely using dissipation.Comment: 15 pages and 8 Figure

Nine years of comparative effectiveness research education and training: initiative supported by the PhRMA Foundation

The term comparative effectiveness research (CER) took center stage with passage of the American Recovery and Reinvestment Act (2009). The companion US$1.1 billion in funding prompted the launch of initiatives to train the scientific workforce capable of conducting and using CER. Passage of the Patient Protection and Affordable Care Act (2010) focused these initiatives on patients, coining the term ‘patient-centered outcomes research’ (PCOR). Educational and training initiatives were soon launched. This report describes the initiative of the Pharmaceutical Research and Manufacturers Association of America (PhRMA) Foundation. Through provision of grant funding to six academic Centers of Excellence, to spearheading and sponsoring three national conferences, the PhRMA Foundation has made significant contributions to creation of the scientific workforce that conducts and uses CER/PCOR

Optimal Generators for Quantum Sensing

We propose a computationally efficient method to derive the unitary evolution that a quantum state is most sensitive to. This allows one to determine the optimal use of an entangled state for quantum sensing, even in complex systems where intuition from canonical squeezing examples breaks down. In this paper we show that the maximal obtainable sensitivity using a given quantum state is determined by the largest eigenvalue of the quantum Fisher information matrix (QFIM) and, importantly, the corresponding evolution is uniquely determined by the coinciding eigenvector. Since we optimize the process of parameter encoding rather than focusing on state preparation protocols, our scheme is relevant for any quantum sensor. This procedure naturally optimizes multiparameter estimation by determining, through the eigenvectors of the QFIM, the maximal set of commuting observables with optimal sensitivity.Comment: 7 pages, 2 figure

Global magnetohydrodynamic simulation of the 15 March 2013 coronal mass ejection event-Interpretation of the 30-80 MeV proton flux

The coronal mass ejection (CME) event on 15 March 2013 is one of the few solar events in Cycle 24 that produced a large solar energetic particle (SEP) event and severe geomagnetic activity. Observations of SEP from the ACE spacecraft show a complex time-intensity SEP profile that is not easily understood with current empirical SEP models. In this study, we employ a global three-dimensional (3-D) magnetohydrodynamic (MHD) simulation to help interpret the observations. The simulation is based on the H3DMHD code and incorporates extrapolations of photospheric magnetic field as the inner boundary condition at a solar radial distance (r) of 2.5 solar radii. A Gaussian-shaped velocity pulse is imposed at the inner boundary as a proxy for the complex physical conditions that initiated the CME. It is found that the time-intensity profile of the high-energy (>10 MeV) SEPs can be explained by the evolution of the CME-driven shock and its interaction with the heliospheric current sheet and the nonuniform solar wind. We also demonstrate in more detail that the simulated fast-mode shock Mach number at the magnetically connected shock location is well correlated (r_(cc) ≥ 0.7) with the concurrent 30–80 MeV proton flux. A better correlation occurs when the 30–80 MeV proton flux is scaled by r^(−1.4)(r_(cc) = 0.87). When scaled by r^(−2.8), the correlation for 10–30 MeV proton flux improves significantly from r_(cc) = 0.12 to r_(cc) = 0.73, with 1 h delay. The present study suggests that (1) sector boundary can act as an obstacle to the propagation of SEPs; (2) the background solar wind is an important factor in the variation of IP shock strength and thus plays an important role in manipulation of SEP flux; (3) at least 50% of the variance in SEP flux can be explained by the fast-mode shock Mach number. This study demonstrates that global MHD simulation, despite the limitation implied by its physics-based ideal fluid continuum assumption, can be a viable tool for SEP data analysis

Biomarkers of Endocannabinoid System Activation in Severe Obesity

Obesity is a worldwide epidemic, and severe obesity is a risk factor for many diseases, including diabetes, heart disease, stroke, and some cancers. Endocannabinoid system (ECS) signaling in the brain and peripheral tissues is activated in obesity and plays a role in the regulation of body weight. The main research question here was whether quantitative measurement of plasma endocannabinoids, anandamide, and related N-acylethanolamines (NAEs), combined with genotyping for mutations in fatty acid amide hydrolase (FAAH) would identify circulating biomarkers of ECS activation in severe obesity.Plasma samples were obtained from 96 severely obese subjects with body mass index (BMI) of > or = 40 kg/m(2), and 48 normal weight subjects with BMI of < or = 26 kg/m(2). Triple-quadrupole mass spectroscopy methods were used to measure plasma ECS analogs. Subjects were genotyped for human FAAH gene mutations. The principal analysis focused on the FAAH 385 C-->A (P129T) mutation by comparing plasma ECS metabolite levels in the FAAH 385 minor A allele carriers versus wild-type C/C carriers in both groups. The main finding was significantly elevated mean plasma levels of anandamide (15.1+/-1.4 pmol/ml) and related NAEs in study subjects that carried the FAAH 385 A mutant alleles versus normal subjects (13.3+/-1.0 pmol/ml) with wild-type FAAH genotype (p = 0.04), and significance was maintained after controlling for BMI.Significantly increased levels of the endocannabinoid anandamide and related NAEs were found in carriers of the FAAH 385 A mutant alleles compared with wild-type FAAH controls. This evidence supports endocannabinoid system activation due to the effect of FAAH 385 mutant A genotype on plasma AEA and related NAE analogs. This is the first study to document that FAAH 385 A mutant alleles have a direct effect on elevated plasma levels of anandamide and related NAEs in humans. These biomarkers may indicate risk for severe obesity and may suggest novel ECS obesity treatment strategies

Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy

Background: The treatment of high-risk neuroblastoma patients consists of multimodal induction therapy to achieve remission followed by consolidation therapy to prevent relapses. However, the type of consolidation therapy is still discussed controversial. We applied metronomic chemotherapy in the prospective NB90 trial and monoclonal anti-GD2-antibody (MAB) ch14.18 in the NB97 trial. Here, we present the long term outcome data of the patient cohort. Methods: A total of 334 stage 4 neuroblastoma patients one year or older were included. All patients successfully completed the induction therapy. In the NB90 trial, 99 patients received at least one cycle of the oral maintenance chemotherapy (NB90 MT, 12 alternating cycles of oral melphalan/etoposide and vincristine/cyclophosphamide). In the NB97 trial, 166 patients commenced the MAB ch14.18 consolidation therapy (six cycles over 12 months). Patients who received no maintenance therapy according to the NB90 protocol or by refusal in NB97 (n = 69) served as controls. Results: The median observation time was 11.11 years. The nine-year event-free survival rates were 41 ± 4%, 31 ± 5%, and 32 ± 6% for MAB ch14.18, NB90 MT, and no consolidation, respectively (p = 0.098). In contrast to earlier reports, MAB ch14.18 treatment improved the long-term outcome compared to no additional therapy (p = 0.038). The overall survival was better in the MAB ch14.18-treated group (9-y-OS 46 ± 4%) compared to NB90 MT (34 ± 5%, p = 0.026) and to no consolidation (35 ± 6%, p = 0.019). Multivariable Cox regression analysis revealed ch14.18 consolidation to improve outcome compared to no consolidation, however, no difference between NB90 MT and MAB ch14.18-treated patients was found. Conclusions: Follow-up analysis of the patient cohort indicated that immunotherapy with MAB ch14.18 may prevent late relapses. Finally, metronomic oral maintenance chemotherapy also appeared effective

Measuring the Burden of Neglected Tropical Diseases: The Global Burden of Disease Framework

Reliable, comparable information about the main causes of disease and injury in populations, and how these are changing, is a critical input for debates about priorities in the health sector. Traditional sources of information about the descriptive epidemiology of diseases, injuries, and risk factors are generally incomplete, fragmented, and of uncertain reliability and comparability. The Global Burden of Disease (GBD) study has provided a conceptual and methodological framework to quantify and compare the health of populations using a summary measure of both mortality and disability, the disability-adjusted life year (DALY)